CD4+ T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival.
暂无分享,去创建一个
A. Waisman | C. Ubeda | R. Flavell | M. Prinz | Nir Yogev | T. Bedke | Yasushi Kobayashi | L. Brockmann | D. Lukas | T. Regen | Andrew L Croxford | Alexei Nikolav | N. Hövelmeyer | E. von Stebut | K. Maloy | N. Gagliani | S. Huber | Tommy Regen
[1] K. Garcia,et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10 , 2021, Science.
[2] Steffen Jung,et al. Interleukin-10 Prevents Pathological Microglia Hyperactivation following Peripheral Endotoxin Challenge. , 2020, Immunity.
[3] S. Peddada,et al. Analysis of compositions of microbiomes with bias correction , 2020, Nature Communications.
[4] T. Bedke,et al. Title: IL-10-producing T cells and their dual functions. , 2019, Seminars in immunology.
[5] Deepali V. Sawant,et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion , 2019, Nature Immunology.
[6] J. Gustafsson,et al. Molecular and functional heterogeneity of IL-10-producing CD4+ T cells , 2018, Nature Communications.
[7] H. Ueno,et al. A CD4+ T cell population expanded in Lupus blood provides B cell help through IL10 and succinate , 2018, Nature Medicine.
[8] David M. Schauder,et al. Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection , 2018, Nature Communications.
[9] H. Ueno,et al. A CD4+ T cell population expanded in Lupus blood provides B cell help through IL10 and succinate , 2018, Nature Medicine.
[10] G. Gusarova,et al. Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution , 2018, Immunity.
[11] M. Olszewski,et al. Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection , 2018, The Journal of Immunology.
[12] R. Flavell,et al. Role of IL-10 Receptor Signaling in the Function of CD4+ T-Regulatory Type 1 cells: T-Cell Therapy in Patients with Inflammatory Bowel Disease. , 2018, Critical reviews in immunology.
[13] S. Snapper,et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.
[14] W. Yao,et al. Interleukin-10 reorganizes the cytoskeleton of mature dendritic cells leading to their impaired biophysical properties and motilities , 2017, PloS one.
[15] A. Waisman,et al. TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity , 2017, Proceedings of the National Academy of Sciences.
[16] Francis J. Huber,et al. IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo , 2017, The Journal of Immunology.
[17] M. Fathy,et al. Association of IL-10 gene polymorphisms and susceptibility to Juvenile Idiopathic Arthritis in Egyptian children and adolescents: a case-control study , 2017, Italian Journal of Pediatrics.
[18] Paul J. McMurdie,et al. DADA2: High resolution sample inference from Illumina amplicon data , 2016, Nature Methods.
[19] Søren Brunak,et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci , 2016, Nature Genetics.
[20] G. Lutfalla,et al. IL10, A Tale of an Evolutionarily Conserved Cytokine across Vertebrates. , 2016, Critical reviews in immunology.
[21] T. Donner,et al. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. , 2015, Cytokine.
[22] B. Bernstein,et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation , 2015, Nature.
[23] P. Vogel,et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T cell-mediated colitis , 2014, Nature Communications.
[24] C. Klein,et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. , 2014, Immunity.
[25] G. Friedlander,et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. , 2014, Immunity.
[26] B. Grimbacher,et al. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. , 2014, Current topics in microbiology and immunology.
[27] A. Hoerauf,et al. T‐cell‐derived, but not B‐cell‐derived, IL‐10 suppresses antigen‐specific T‐cell responses in Litomosoides sigmodontis‐infected mice , 2013, European journal of immunology.
[28] Pelin Yilmaz,et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..
[29] P. Vogel,et al. This information is current as Central Nervous System Autoimmunity Dynamics and Paradoxically Promotes The T Cell Response to IL-10 Alters Cellular , 2012 .
[30] T. Mcclanahan,et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. , 2012, Cancer research.
[31] B. Clausen,et al. IL-10 controls dendritic cell-induced T-cell reactivation in the skin to limit contact hypersensitivity. , 2012, The Journal of allergy and clinical immunology.
[32] T. Mcclanahan,et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.
[33] C. Klein,et al. IL‐10 and IL‐10 receptor defects in humans , 2011, Annals of the New York Academy of Sciences.
[34] J. Bluestone,et al. Control of TH17 cells occurs in the Small Intestine , 2011, Nature.
[35] Y. Wan,et al. Memory/effector (CD45RBlo) CD4 T cells are controlled directly by IL-10 and cause IL-22–dependent intestinal pathology , 2011, The Journal of experimental medicine.
[36] R. Caspi,et al. Faculty Opinions recommendation of Fate mapping of IL-17-producing T cells in inflammatory responses. , 2011 .
[37] A. Rudensky,et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.
[38] Francis J. Huber,et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. , 2011, Immunity.
[39] M. Veldhoen,et al. Fate mapping of interleukin 17-producing T cells in inflammatory responses , 2011, Nature Immunology.
[40] A. Waisman,et al. Genetic proof for the transient nature of the Th17 phenotype , 2010, European journal of immunology.
[41] L. Groebe,et al. Monocytes/macrophages and/or neutrophils are the target of IL‐10 in the LPS endotoxemia model , 2010, European journal of immunology.
[42] B. Cai,et al. Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis , 2010, Molecular Biology Reports.
[43] A. Schäffer,et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.
[44] Gisen Kim,et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis , 2009, Nature Immunology.
[45] T. Mcclanahan,et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.
[46] E. Riley,et al. IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.
[47] E. Chi,et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. , 2008, Immunity.
[48] A. O’Garra,et al. TH1 cells control themselves by producing interleukin-10 , 2007, Nature Reviews Immunology.
[49] V. Kuchroo,et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation , 2007, Nature Medicine.
[50] Stefan Wirtz,et al. Chemically induced mouse models of intestinal inflammation , 2007, Nature Protocols.
[51] C. Loddenkemper,et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.
[52] F. Sutterwala,et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. , 2006, Immunity.
[53] D. Raoult,et al. The two faces of interleukin 10 in human infectious diseases. , 2006, The Lancet. Infectious diseases.
[54] K. Foulds,et al. IL-10 Is Required for Optimal CD8 T Cell Memory following Listeria monocytogenes Infection , 2006, The Journal of Immunology.
[55] K. Rajewsky,et al. T Cell–specific Inactivation of the Interleukin 10 Gene in Mice Results in Enhanced T Cell Responses but Normal Innate Responses to Lipopolysaccharide or Skin Irritation , 2004, The Journal of experimental medicine.
[56] Stefan Wirtz,et al. TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .
[57] W. Ip,et al. Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus , 2004, Genes and Immunity.
[58] R. Kiesslich,et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.
[59] S. Kotenko,et al. The expanded family of class II cytokines that share the IL‐10 receptor‐2 (IL‐10R2) chain , 2004, Journal of leukocyte biology.
[60] David Gray,et al. B cells regulate autoimmunity by provision of IL-10 , 2002, Nature Immunology.
[61] K. Asadullah,et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. , 2002, The Journal of investigative dermatology.
[62] C. Demangel,et al. Autocrine IL‐10 impairs dendritic cell (DC)‐derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL‐12 production , 2002, European journal of immunology.
[63] M. Lotze,et al. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. , 2001, Blood.
[64] R. Coffman,et al. Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.
[65] P. Rutgeerts,et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .
[66] T. van der Poll,et al. Proinflammatory Effects of IL-10 During Human Endotoxemia1 , 2000, The Journal of Immunology.
[67] H. Weiner,et al. IL-10 is critical in the regulation of automimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice , 1998, Journal of Neuroimmunology.
[68] W Sterry,et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.
[69] Wei Wu,et al. Identification and functional characterization of a second chain of the interleukin‐10 receptor complex , 1997, The EMBO journal.
[70] L. Nagelkerken,et al. IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. , 1997, International Immunology.
[71] B. Groner,et al. IL‐10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes , 1996, FEBS letters.
[72] C. Brosnan,et al. IL‐10 fails to abrogate experimental autoimmune encephalomyelitis , 1996, Journal of neuroscience research.
[73] A. Miyajima,et al. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain , 1995, Molecular and cellular biology.
[74] K. Rajewsky,et al. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. , 1995, Nucleic acids research.
[75] B. Fleischer,et al. Interleukin‐10 prevents experimental allergic encephalomyelitis in rats , 1994, European journal of immunology.
[76] Y. Lévy,et al. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.
[77] K. Rajewsky,et al. Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.
[78] T. Mosmann,et al. The role of IL-10 in crossregulation of TH1 and TH2 responses. , 1991, Immunology today.
[79] T. Mosmann,et al. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.